SCHEMBL4295568

SCHEMBL4295568

CC(C)(C)c1ccc(OCC(=O)Nc2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.73
EPAS1 Q99814 1/20 0.73
EPHX2 P34913 1/20 0.62
NR1H4 Q96RI1 1/20 0.62
HCAR2 Q8TDS4 1/20 0.62
TRPV1 Q8NER1 4/20 0.61
LMNA P02545 3/20 0.61
NPSR1 Q6W5P4 2/20 0.61
ALDH1A1 P00352 1/20 0.61
MAPT P10636 1/20 0.61
HTT P42858 1/20 0.61
NR4A2 P43354 1/20 0.60
RXRA P19793 1/20 0.60
RXRB P28702 1/20 0.60
POLB P06746 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.57
MDH1 P40925 1/20 0.57
MDH2 P40926 1/20 0.57
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31503974 0.92 TRPV1 (0.70) HIF1AEPAS1HCAR2TRPV1LMNA
SCHEMBL4293576 0.88 ALDH1A1 (0.67) HIF1AEPAS1TRPV1LMNANPSR1
SCHEMBL21588757 0.87 KMT2A (0.65) HIF1AEPAS1NR1H4HCAR2LMNA
SCHEMBL27090192 0.86 TRPV1 (0.64) HIF1AEPAS1HCAR2TRPV1LMNA
SCHEMBL21588706 0.86 MEN1 (0.64) HIF1AEPAS1TRPV1LMNANPSR1
SCHEMBL2954418 0.85 HIF1A (1.00) HIF1AEPAS1NR1H4HCAR2ALDH1A1
SCHEMBL30460318 0.85 HIF1A (1.00) HIF1AEPAS1NR1H4HCAR2ALDH1A1
SCHEMBL5422115 0.85 MAPT (0.74) HCAR2LMNAALDH1A1MAPTHTT
SCHEMBL11427645 0.83 NR4A2 (0.70) HIF1AEPAS1EPHX2NR1H4HCAR2
SCHEMBL7302398 0.82 SMN1; SMN2 (0.72) EPHX2NR1H4TRPV1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394799-B2 Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2013-03-12 US disclosed
US-20090306078-A1 COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-12-10 US disclosed
WO-2008004798-A1 COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306078-A1 COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT HIF1AN, HIF1A, VHL HIF1A 2/4885EPAS1 14/4885EPHX2 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.